ATE249243T1 - Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat - Google Patents
Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelatInfo
- Publication number
- ATE249243T1 ATE249243T1 AT97902867T AT97902867T ATE249243T1 AT E249243 T1 ATE249243 T1 AT E249243T1 AT 97902867 T AT97902867 T AT 97902867T AT 97902867 T AT97902867 T AT 97902867T AT E249243 T1 ATE249243 T1 AT E249243T1
- Authority
- AT
- Austria
- Prior art keywords
- chelate
- toxin
- drug
- antibodies
- net load
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Radiology & Medical Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58607596A | 1996-01-11 | 1996-01-11 | |
PCT/US1997/000307 WO1997025069A1 (en) | 1996-01-11 | 1997-01-06 | Antibodies with reduced net positive charge |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE249243T1 true ATE249243T1 (de) | 2003-09-15 |
Family
ID=24344206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97902867T ATE249243T1 (de) | 1996-01-11 | 1997-01-06 | Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0873139B1 (de) |
JP (2) | JP2000503301A (de) |
KR (1) | KR100485240B1 (de) |
AT (1) | ATE249243T1 (de) |
AU (1) | AU730388B2 (de) |
CA (1) | CA2242750C (de) |
DE (1) | DE69724761T2 (de) |
ES (1) | ES2206683T3 (de) |
RU (1) | RU2219949C2 (de) |
WO (1) | WO1997025069A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005047903A1 (en) * | 2003-11-07 | 2005-05-26 | Upstate Usa. Inc. | A method for generating antibody conjugates that preserves antigen recognition |
WO2013184200A1 (en) * | 2012-06-05 | 2013-12-12 | Msm Protein Technologies | Human monoclonal antibodies against human chemokine receptor ccr7 |
ES2600154T3 (es) | 2012-07-04 | 2017-02-07 | F. Hoffmann-La Roche Ag | Anticuerpos antiteofilina y métodos de uso |
RU2630296C2 (ru) | 2012-07-04 | 2017-09-06 | Ф. Хоффманн-Ля Рош Аг | Антитела к биотину и способы их применения |
NZ701040A (en) | 2012-07-04 | 2017-02-24 | Hoffmann La Roche | Covalently linked antigen-antibody conjugates |
MX373856B (es) | 2014-01-03 | 2025-03-04 | Hoffmann La Roche | Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos. |
WO2015101586A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
RU2682754C2 (ru) | 2014-01-03 | 2019-03-21 | Ф. Хоффманн-Ля Рош Аг | Конъюгаты полипептидного токсина и антитела, соединенных ковалентной связью |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4753894A (en) * | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
WO1988007553A1 (en) * | 1987-03-26 | 1988-10-06 | Teijin Limited | Process for preparing antibody complex |
WO1991007991A1 (en) * | 1989-11-30 | 1991-06-13 | Mallinckrodt Medical, Inc. | Method for preparing a metal-radionuclide-labelled protein |
US5194594A (en) * | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
SE9100142L (sv) * | 1991-01-17 | 1992-07-18 | Bengt Sandberg | En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal |
CA2134239C (en) * | 1992-06-09 | 2004-11-23 | Donald B. Axworthy | Pretargeting methods and compounds |
US5578287A (en) * | 1992-06-09 | 1996-11-26 | Neorx Corporation | Three-step pretargeting methods using improved biotin-active agent |
JPH0853499A (ja) * | 1994-08-10 | 1996-02-27 | Green Cross Corp:The | キメラ抗体Fab断片のオリゴマー体 |
-
1997
- 1997-01-06 WO PCT/US1997/000307 patent/WO1997025069A1/en active IP Right Grant
- 1997-01-06 KR KR1019980705339A patent/KR100485240B1/ko not_active IP Right Cessation
- 1997-01-06 AT AT97902867T patent/ATE249243T1/de active
- 1997-01-06 RU RU98115277/15A patent/RU2219949C2/ru not_active IP Right Cessation
- 1997-01-06 AU AU16939/97A patent/AU730388B2/en not_active Ceased
- 1997-01-06 DE DE69724761T patent/DE69724761T2/de not_active Expired - Lifetime
- 1997-01-06 JP JP9525384A patent/JP2000503301A/ja active Pending
- 1997-01-06 ES ES97902867T patent/ES2206683T3/es not_active Expired - Lifetime
- 1997-01-06 CA CA002242750A patent/CA2242750C/en not_active Expired - Fee Related
- 1997-01-06 EP EP97902867A patent/EP0873139B1/de not_active Expired - Lifetime
-
2012
- 2012-02-08 JP JP2012024825A patent/JP2012131808A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE69724761T2 (de) | 2004-08-05 |
DE69724761D1 (de) | 2003-10-16 |
CA2242750C (en) | 2007-03-27 |
JP2012131808A (ja) | 2012-07-12 |
EP0873139A1 (de) | 1998-10-28 |
WO1997025069A1 (en) | 1997-07-17 |
ES2206683T3 (es) | 2004-05-16 |
AU1693997A (en) | 1997-08-01 |
EP0873139B1 (de) | 2003-09-10 |
JP2000503301A (ja) | 2000-03-21 |
RU2219949C2 (ru) | 2003-12-27 |
CA2242750A1 (en) | 1997-07-17 |
KR100485240B1 (ko) | 2006-10-24 |
KR19990077198A (ko) | 1999-10-25 |
AU730388B2 (en) | 2001-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2090700A1 (en) | Modified antibodies with controlled clearance time | |
TR200101751T2 (tr) | Poliol-IFN-beta konjugatları | |
DE69934337D1 (de) | Konjugate zur Behandlung von Entzündungskrankheiten und von assozierter Gewebeschädigung | |
ATE517125T1 (de) | ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN | |
ATE383430T1 (de) | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren | |
FR15C0033I2 (fr) | Support macromoleculaire sur base de dextran pour l'administration d'un agent diagnostique ou therapeutique | |
MXPA02011656A (es) | Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos. | |
EP0329184A3 (de) | Antimere und antimere Konjugation | |
NO901986L (no) | Nytt antistoff-leveringssystem for biologisk respons-modifiserende midler. | |
BR0014652A (pt) | Fabricação de conjugados de agente terapêutico-poliglutamato | |
BR0015506A (pt) | Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças | |
NO20010021D0 (no) | Trifunksjonelt reagens for konjugering til et biomolekyl | |
ATE249243T1 (de) | Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat | |
ATE192047T1 (de) | Bicylclische, polyazamakrocyclocarbonsäure- komplexe, konjugate, herstellung und verwendung als kontraststoffe | |
DE69223504D1 (de) | Bicycloazamakrocyclophosphon-Säure, Komplexe, Konjugate, Kontrastmittel und Herstellung | |
FI933506A0 (fi) | Bicyklopolyazamakrocyklokarboxylsyrakomplex, konjugat daerav, foerfarande foer deras framstaellning och anvaendning som kontrastmedel | |
BR9714945A (pt) | Composição topicamente aplicável para introdução de fármacos peptidaceosos em organismos vivos | |
NO954442L (no) | Bicyklopolyazamakrocyklofosfonsyrer, deres komplekser og konjugater, for anvendelse som kontrastmidler, og fremgangsmåter for deres fremstilling | |
Muzykantov | Conjugation of catalase to a carrier antibody via a streptavidinŐbiotin cross‐linker | |
TR199700842T1 (xx) | �nsan DNase I Varyantlar�. | |
BR9913429A (pt) | Anticorpos bifuncionais e seu uso na objetivação de agentes antitumor | |
RU93053897A (ru) | Комплексы бициклополиазамакроциклокарбоновых кислот, их конъюгаты, фармацевтическая композиция, способ диагностики, набор и способ получения | |
WO1998051792A8 (en) | Fac molecules and uses thereof | |
MY109649A (en) | Bicyclopol yazamacrocyclocarboxylic acid complexes, and conjugates, processes for their prepration, and use as contrast agents | |
MY141501A (en) | Bicyclopolyazamacrocyclophosphonic acids, their complexes and conjugates, for use as contrast agents and processes for their preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0873139 Country of ref document: EP |